Report of the council on scientific affairs: Methadone maintenance and needle-exchange programs to reduce the medical and public health consequences of drug abuse

Journal of Addictive Diseases

Volumn 20, Issue 2, 2001, Pages 15-40

  Yoast, Richard ^a   Williams, Michael A ^a   Deitchman, Scott D ^a   Champion, Hunter C ^a  

^a AMERICAN MEDICAL ASSOCIATION   (United States)

Author keywords

Drug abuse; Methadone maintenance therapy; Pathogens

Indexed keywords

METHADONE;

ARTICLE; DRUG ABUSE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MAINTENANCE THERAPY; NEEDLE; PUBLIC HEALTH SERVICE; SYRINGE;

COMMUNITY MENTAL HEALTH SERVICES; COST-BENEFIT ANALYSIS; HEROIN DEPENDENCE; HUMANS; METHADONE; NARCOTICS; NEEDLE-EXCHANGE PROGRAMS; UNITED STATES;

EID: 0034775384     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v20n02_03     Document Type: Article

References (112)

1. Paone D, Des Jarlais DC, Gangloff R, Milliken J, Friedman SR. Syringe exchange: IV prevention, key findings, and future directions. Int J Addict. 1995; 30:1647-1683.
2. Council on Scientific Affairs. Report 8: Reduction of the medical and public health consequences of drug abuse. Chicago: American Medical Association; 1997.
3. Kreek MD. A personal retrospective and prospective viewpoint. In: Parrino MW. State methadone treatment guidelines-treatment improvement protocol (TIP), series 1. Rockville, MD: Center for Substance Abuse Treatment; 1993;133-143.
4. Dole VP, Nyswander ME. A medical treatment for diacetyl-morphine (heroin) addiction. JAMA. 1965; 193:646.
5. Hubbard RL, Marsden ME, Rachal JV, et al. Drug abuse treatment: a national study of effectiveness. Chapel Hill, NC: University of North Carolina Press; 1989.
6. Gerstein DR, Harwood HJ. Treating drug problems: a study of the evolution, effectiveness, and financing of public and private drug treatment systems. Washington, DC: National Academy Press; 1990.
7. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214-226.
8. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence. JAMA. 2000;283:1303-1310.
9. Hubbard RL, Craddock SG, Flynn, PM, et al. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav. 1997;4:261-278.
10. Gossop M, Marsden J, Stewart D, et al. The National Treatment Outcome Research Study in the United Kingdom: six-month follow-up outcomes. Psychol Addict Behav. 1997;4:324-337.
11. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Outcome after methadone treatment: influence of prior treatment factors and current treatment status. Drug Alcohol Dependence. 1994;35:223-230.
12. National Development and Research Institute. Drug Abuse Treatment Outcome Study (DATOS). Available at: www.datos.org/highlights.html. Accessed: April 3, 1998.
13. Ries R. Assessment and treatment of patients with coexisting mental illness and alcohol and other drug abuse-treatment improvement protocol (TIP), series 9. Rockville, MD: Center for Substance Abuse Treatment; 1994.
14. Ralston GE, Wilson P. Methadone programmes-the cost and benefits to society and the individual. Pharmaco Economics. 1996;10:321-326.
15. National Institutes of Health, Consensus Development Conference Statement. Effective medical treatment of opiate addiction. NIH Consensus Statement No. 108. November 17-19, 1997. Available at: http://odp.od.nih.gov/consensus/cons/108/108_ statement.htm. Accessed: May 17, 2000.
16. US Dept. of Health and Human Services. The National Treatment Improvement Evaluation Study-NTIES. Rockville, MD: SAMHSA-Center for Substance Abuse Treatment; 1997.
17. Swan N. Research demonstrates long-term benefits of methadone treatment. NIDA Notes. 1994:9(4).
18. Farrell M, Neeleman J, Gossop M, et al. Methadone provision in the European union. Int J Drug Pol. 1995;6:168-172.
19. Verthein U, Raschke P, Kalke J. Methadone therapy in Hamburg. Eur Addict Res. 1995;1:99-105.
20. Buring EC, van Brussel GH, van Santen G. The ‘methadone by bus’ project in Amsterdam. Br J Addict. 1990;85:1247-1250.
21. Ward J, Mattick RP, Hall W. Key issues in methadone maintenance treatment. Kensington, Australia: New South Wales University Press; 1992.
22. Caplehorn JRM, Batey RG. Methadone maintenance in Australia. J Drug Issues. 1992;22:672.
23. Buning E. Methadone in Europe. Int J Drug Pol. 1994;5:221-225.
24. Rettig RA, Yarmolinsky A, eds. Federal regulation of methadone treatment. Washington, DC: National Academy Press; 1995.
25. Rettig RA, Yarmolinsky A, eds. Federal regulation of methadone treatment. Washington, DC: National Academy Press; 1995.
26. Young L. Improving quality and oversight of methadone treatment. Press Release. July 22, 1999. USDHHS, SAMHSA. Available at: http://www.samhsa.gov/press/99/990722fs.htm.
27. Epstein JF, Gfroerer JC. Heroin abuse in the United States. OAS working paper. Rockville, MD: Office of Applied Studies, SAMHSA; 1997, p.4.
28. Maddux JF, Prihoda TJ, Vogtsberger KN. The relationship of methadone dose and other variables to outcomes of methadone maintenance. Am J Addict. 1997; 6:246-255.
29. Joseph H. Methadone maintenance treatment and clinical issues. In: Chemical Dependency Research Working Group. Methadone treatment works: a compendium for methadone maintenance treatment. part I (Monograph). New York: New State Office of Alcoholism and Substance Abuse Services; December 1994.
30. Payte JT, Khuri ET. Principles of methadone dose determination. In: Parrino MW. State methadone treatment guidelines-treatment improvement protocol (TIP), series 1. Rockville, MD: Center for Substance Abuse Treatment; 1993:1-9.
31. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs. high-dose methadone in the treatment of opioid dependence. JAMA. 1999;281:1000-1005.
32. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57:395-404.
33. Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999;31:95-102.
34. Ward J, Hall W, Mattick RP. Role of maintenance in opioid dependence. Lancet. 1999;353:221-226.
35. Bach PB, Lantos J. Methadone dosing, heroin affordability, and the severity of addiction. Am J Public Health. 1999;89:662-665.
36. Rosenbaum M. The demedicalization of methadone maintenance. J Psychoactive Drugs. 1995;27:145-149.
37. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health. 1998;88:34-39.
38. Parrino MW. Overview: current treatment realities and future trends. In: Parrino MW. State methadone treatment guidelines-treatment improvement protocol (TIP), series 1. Rockville, MD: Center for Substance Abuse Treatment; 1993:1-9.
39. Goldsmith RJ, Larimer ME, Marlatt GA. Chapter 4-Abstinence as the goal of treatment: two views. In: Miller NS, ed. Principles of addiction medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1994.
40. Payte JT, Khuri E, Joseph H, Woods, J. The methadone maintained patient and the treatment of pain. In: Chemical Dependency Research Working Group. Methadone treatment works: a compendium for methadone maintenance treatment. part I. (Monograph) New York: New State Office of Alcoholism and Substance Abuse Services; December 1994.
41. Dole VP. Hazards of process regulations-the example of methadone maintenance. JAMA. 1992;267:2234-2235.
42. McCarty D, Frank RG, Denmead GC. Methadone maintenance and state Medicaid managed care programs. Milbank Q. 1999;77:341-362, 274.
43. Lewis DC. Access to narcotic addiction treatment and medical care: prospects for the expansion of methadone maintenance treatment. J Addict Dis. 1999;18:5-21.
44. Rosenbaum M, Washburn A, Knight K, Kelley M, Irwin J. Treatment as harm reduction, defunding as harm maximization: the case of methadone maintenance. J Psychoactive Drugs. 1996;28:241-249.
45. Wenger LD, Rosenbaum M. Drug treatment on demand-not! J Psychoactive Drugs. 1994;26:1-11.
46. National Institutes of Health. Interventions to prevent HIV risk behaviors. NIH Consensus Statement, February 11-13. 1997;5(2):1-41.
47. Gerstein DR, Harwood HJ, eds. Treating drug problems. vol. I. a study of the evolution, effectiveness, and financing of public and private drug treatment systems. Washington, DC: National Academy Press; 1990.
48. Yarmolinsky A, Pechura CM. Methadone revisited. Issues Science Technol. 1996; Spring: 38-42.
49. O’Brien CP, Woody GE, McLellan AT. Enhancing the effectiveness of methadone using psychotherapeutic interventions. In: Integrating behavioral therapies with medications in the treatment of drug dependence (Research Monograph 150). Rockville, MD: National Institute on Drug Abuse; 1995; 5-18.
50. McLellan AT, Alterman AI, Metzger DS, et al. Similarity of outcome predictors across opioid, cocaine, and alcohol treatments: role of treatment services. J Consult Clin Psychol. 1994;62:1141-1158.
51. Crits-Christoph P, Siqueland L. Psychosocial treatment for drug abuse. Selected review and recommendations for national health care. Arch Gen Psychiatry. 1996;53:749-756.
52. Council on Scientific Affairs Report. Methadone maintenance in private practice. Chicago, IL: American Medical Association; 1994. Available at: http://www.ama-assn.org/med-sci/csa/1994/meth.htm.
53. Novick DM, Joseph H. Medical maintenance: the treatment of chronic opioid dependence in general medical practice. J Substance Abuse Treat. 1991;8:233-239.
54. Herman M, Gourevitch MN. Integrating primary care and methadone maintenance treatment: implementation issues. J Addict Dis. 1997;16:91-102.
55. Novick DM, Pascarelli EF, Joseph H. Methadone maintenance patients in general medical practice: a preliminary report. JAMA. 1988:259:3299-3302.
56. McNeely J, Drucker E, Hartel D, Tuchman E. Office-based methadone prescribing: acceptance by inner-city practitioners in New York. J Urban Health. 2000; 77:96-102.
57. Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices. JAMA. 2000;283:1343-1348.
58. Matheson C, Bond CM, Hickey F. Prescribing and dispensing for drug misusers in primary care: current practice in Scotland. Fam Pract. 1999;16:375-379.
59. Keen J, Rowse G, Mathers N, Campbell M, Seivewright N. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? Br J Gen Pract. 2000; 50:48-49.
60. Gossop M, Marsden J, Stewart D, Lehmann P, Strang J. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract. 1999;49:31-34.
61. Payte JT. Methadone maintenance treatment: the first thirty years. J Psychoactive Drugs. 1997;29:149-153.
62. Parrino MW. State methadone treatment guidelines-treatment improvement protocol (TIP), series 1. Rockville, MD: Center for Substance Abuse Treatment; 1993.
63. Health and Human Services Press Office. Research shows needle exchange programs reduce HIV infections without increasing drug use. Washington, DC: USDHHS Press Office, April 10, 1998.
64. Centers for Disease Control and Prevention. Update: syringe-exchange pro- grams-United States, 1997. MMWR. 1998;47:652-655.
65. Rosenberg PS, Biggar RJ. Trends in HIV incidence among young adults in the United States. JAMA. 1998;279(23):1894-1899.
66. Kral AH, Bluthenthal RN, Booth RE, Watters JK, NIDA Cooperative Agreement Steering Committee. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108-113.
67. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S6-S10.
68. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S11-S19.
69. Gostin LO, Lazzarini Z, Jones S, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. JAMA. 1997;277:53-62.
70. Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S60-S70.
71. Gleghorn AA, Gee G, Vlahov D. Pharmacists’ attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquired Immune Defic Syndr Human Retrovirol. 1998; 18(suppl I):S89-S93.
72. Wright-De Aguero L, Weinstein B, Jones TS, Miles J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers’ practices. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I): S102-S110.
73. Case P, Beckett GA, Jones TS. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S94-S101.
74. Gostin LO, Lazzarini Z. Prevention of HIV/AIDS among injection drug users: the theory and science of public health and criminal justice approaches to disease prevention. Emory Law J. 1997;46:587-696.
75. Burris S, Finucane D, Gallagher J, Grace J. The legal strategies used in operating syringe exchange programs in the United States. Am J Public Health. 1996; 86:1161-166.
76. Valleroy LA, et al. Impact of increased legal access to needles and syringes on community pharmacies’ need and syringe sales B Connecticut, 1992-1993. J Acquired Immune Defic Syndr Human Retrovirol. 1995;10:73-81.
77. Groseclose SL, Weinstein B, Jones TS, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officer-Connecticut, 1992-1993. J Acquired Immune Defic Syndr Human Retrovirol. 1995; 10:82-89.
78. Diaz T, Chu SY, Weinstein B, Mokotoff E, Jones TS, Supplement to HIV/AIDS Surveillance Group. Injection and syringe sharing among HIV-infected injection drug users: implications for prevention of HIV transmission. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S76-S81.
79. Singer M. Changing the environment of AIDS risk: findings on syringe exchange and pharmacy sales of syringes in Hartford, CT. Med Anthropol. 1997; 18:107-130.
80. Gershon RRM. Infection control basis for recommending one-time use of sterile syringes and aseptic procedures for injection drug users. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S20-S24.
81. Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc. 1999;39:23-26.
82. Mandell W, Vlahon D, Latkin C, Oziemkowska M, Cohn S. Correlates of needle sharing among injection drug users. Am J Public Health. 1994;84:920-923.
83. Rich JD, Strong L, Towe CW, McKenzie M. Obstacles to needle exchange participation in Rhode Island. JAIDS. 1999;21:396-400.
84. Vogt RL, Breda MC, Des Jarlais DC, Gates S, Whiticar P. Hawaii’s statewide syringe exchange program. Am J Public Health. 1998;88:1403-14044.
85. Lurie P, Reingold AL, Bowser B, et al. The public-health impact of needle exchange programs in the United States and abroad. Atlanta, GA: Centers for Disease Control and Prevention; 1993. [Prepared for the Centers for Disease Control by the University of California, Berkeley and San Francisco] Centers for Disease Control and Prevention (1993).
86. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press; 1995. [for the National Research Council and Institute of Medicine].
87. National Institutes of Health. Interventions to prevent HIV risk behaviors. NIH Consensus Statement February 11-13, 1997;5(2):1-41.
88. Des Jarlais DC, Marmor M, Friedman P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health. 2000;90:352-359.
89. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press; 1995.
90. McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S25-S29.
91. Jones TS, Vlahov. Use of sterile syringes and aseptic drug preparation are important components of HIV prevention among injection drug users. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S1-S5.
92. Des Jarlais DC. “Single-use” needles and syringes for the prevention of HIV infection among injection drug users. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S52-S56.
93. Gleghorn AA, Wright-De Aguero L, Flynn C. Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven United States metropolitan areas. S30-S36.
94. Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: effects of syringe exchange programs in four cities. S37-S44.
95. Keyl PM, Gruskin L, Casano K, Montag H, Junge B, Vlahov D. Community support for needle exchange programs and pharmacy sale of syringes: a household survey in Baltimore, Maryland. S82-S88.
96. Macalino GE, Springer KW, Rahman ZS, Vlahov D, Jones TS. Community- based programs for safe disposal of used needles and syringes. S111-S119.
97. Riley E, Beilenson P, Vlahov D, Smith L, Koenig M, Jones TS, Doherty M. Operation red box: a pilot project of needle and syringe drop boxes for injection drug users in East Baltimore. S120-S125.
98. Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquired Immune Defic Syndr Human Retrovirol. 1998; 18(suppl I):S45-S51.
99. Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquired Immune Defic Syndr Human Retrovirol. 1998; 18(suppl I):S126-S132.
100. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S33-S38.
101. Case P, Meehan T, Jones TS. Arrests and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S71-S75.
102. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996. Available at: JAMA HIV/AIDS Information Center, http://www.ama-assn.org
103. Centers for Disease Control and Prevention, Public Health Service, US Dept. of Health and Human Services. HIV prevention bulletin: medical advice for persons who inject illicit drugs. May 1997.
104. Stapleton S. States find needle exchanges effective in HIV prevention. American Medical News. September 8, 1997.
105. Bruneau J, Lamothe F, Franco E, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997;146:994-1002.
106. Remis RS, Bruneau J, Hankins CA. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J Acquired Immune Defic Syndr Human Retrovirol. 1998;18(suppl I):S57-S59.
107. Lurie P. Invited commentary: le mystere de Montreal. Am J Epidemiol. 1997;146:1003-1005.
108. Strathdee SA, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997:Jul;11(8):F59-F65.
109. Schechter MT, et al. Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak. AIDS. 1999;13:F45-F51.
110. Raboud JM, et al. Explosive HIV epidemics in injection drug users-what are the causes and controls? 5th Conf Retrovir Oppor Infect. 1998;104 (abstract no. 133).
111. Bruneau J, Schechter MT. From the lead investigators in Montreal and Vancouver. As submitted to the New York Times for publication and, in abbreviated version published April 9, 1998, p. 27, “The Politics of Needles and AIDS.”
112. Page JB. Needle exchange and reduction of harm: an anthropological view. Med Anthropol. 1997;18:13-33.